Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Polyp
ADR ID BADD_A05936
ADR Hierarchy
08      General disorders and administration site conditions
08.01      General system disorders NEC
08.01.06      Mucosal findings abnormal
08.01.06.010      Polyp
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.02      Miscellaneous and site unspecified neoplasms benign
16.02.02      Neoplasms benign site unspecified NEC
16.02.02.005      Polyp
Description Discrete abnormal tissue masses that protrude into the lumen of the DIGESTIVE TRACT or the RESPIRATORY TRACT. Polyps can be spheroidal, hemispheroidal, or irregular mound-shaped structures attached to the MUCOUS MEMBRANE of the lumen wall either by a stalk, pedunculus, or by a broad base. [MeSH]
MedDRA Code 10061529
MeSH ID D011127
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Polyp NOS | Polyps | Polyp | Hyperplastic polyp | Secretory polyp
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01989Saquinavir mesylate--
BADD_D02007Semaxanib--
BADD_D02028Sirolimus--
BADD_D02029Sitagliptin0.000053%
BADD_D02031Sitaxentan--
BADD_D02047Sodium oxybate0.000590%
BADD_D02053Sofosbuvir0.000282%
BADD_D02105Tacrolimus--
BADD_D02106Tadalafil--
BADD_D02111Tamoxifen--
BADD_D02112Tamoxifen citrate--
BADD_D02137Teduglutide--
BADD_D02140Tegaserode--
BADD_D02165Teriflunomide0.000241%
BADD_D02170Testosterone--
BADD_D02203Thiotepa--
BADD_D02227Tipranavir disodium--
BADD_D02236Tofacitinib0.002845%
BADD_D02250Toremifene citrate--
BADD_D02254Tramadol--
BADD_D02257Trametinib--
BADD_D02299Trisequens--
BADD_D02321Ursodiol--
BADD_D02329Valproic acid--
BADD_D02334Vandetanib--
BADD_D02344Vemurafenib--
BADD_D02362Vinflunine--
BADD_D02373Warfarin0.000236%
BADD_D02375Water--
BADD_D02392Zoledronic acid--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages